Roles of the pathologist in neoadjuvant chemotherapy: Evaluation of response, prognostic and predictive factors;Le pathologiste et la chimiothérapie néoadjuvante: Évaluation de la réponse, fracteurs pronostiques et prédictifs

Annales de Pathologie

Volumn 23, Issue 6, 2003, Pages 555-563

  Penault Llorca, Frédérique ^a   Vincent Salomon, Anne ^b  

^a CENTRE JEAN PERRIN   (France)

^b INSTITUT CURIE   (France)

Author keywords

Breast cancer; Induction chemotherapy; Predictive factor; Prognostic factor; Response to treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST BIOPSY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER SIZE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG SENSITIVITY; FEMALE; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; ONCOGENE NEU; PATHOLOGIST; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PATHOLOGY; PHYSICIAN'S ROLE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 1842523328     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Chollet P, Amat S, Mouret-Reynier MA, Curé H. Les bénéfices de la chimiothérapie néoadjuvante dans le cancer du sein opérable. Osncologie 2002; 4: 34-7.
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
3. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-12.
4. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002; 9: 243-7.
5. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000; 18: 3480-6.
6. Vincent-Salomon A, Carton M, Freneaux P, Palangie T, Beuzeboc P, Mouret E et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 2000; 36: 586-91.
7. Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002; 94: 3107-14.
8. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998; 4: 230-6.
9. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 1456-66.
10. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-8.
11. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995; 180: 297-306.
12. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al. Effect of preoperative chemotherapy on the outcome of 'women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.
13. Cure H, Amat S, Penault-Llorca F, le Bouedec G, Ferriere JP, Mouret-Reynier MA et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat 2002; 76: 37-45.
14. Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, Van Praagh I et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol. 2002; 20: 791-6.
15. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003; 88: 1339-45.
16. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041-6.
17. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi, Br J Cancer 1996; 74: 1458-65.
18. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-6.
19. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
20. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncologica 1999; 38: 597-601.
21. Vargas-Roig LM, Gago FE, Tello O, Martin De Civetta M, Ciocca DR. C-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer 1999; 84: 129-34.
22. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6: 2751-8.
23. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S et al. Relationship between shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001; 85: 1106-12.
24. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-12.
25. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852-4.
26. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003; 22: 1319-25.
27. Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A, Beuzeboc P et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response. Eur J Cancer 2003; 39: 1089-96.
28. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997; 76: 917-22.
29. Mathieu MC, Llombart-Cussac A, Spielmann M, Koscielny S, Travalgli JP, Contesso G. Invasive lobular carcinoma of the breast treated by preoperative chemotherapy. Arch Anat Cytol Path 1988; 46: 308.
30. MacGrogan G, Rudolph P, de Mascarel I, Mauriac L, Durand M, Avril A et al. DNA topoisomerase 11alpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 2003; 89: 666-71.
31. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
32. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001; 19: 4141-9.
33. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3: 593-600.
34. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
35. Remvikos Y, Mosseri V, Zajdela A, Fourquet A, Durand JC, Pouillart P et al. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci 1993; 698: 193-203.
36. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase 11alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-73.
37. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase 11 trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-95.
38. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, Van De Vijver M, MacGrogan G et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003; 14: 406-13.
39. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002; 20: 1304-10.
40. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83: 1480-7.
41. Viens P, Penault-Llorca F, Jacquemier J, Gravis G, Cowen D, Bertucci F et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249-54.
42. Penault-Llorca F, Sastre X, Fiche M, Simony J, Ledoussal V, Ettore F et al. Pathological response to neoadjuvant chemotherapy, final results of a prospective randomized trial of 4 AT vs 4 AC as induction therapy in patients with operable breast cancer, using Sataloff classification. Breast Cancer Res Treat 1999; 57: 67, abstract 248.
43. MacGrogan G, Pallud C, Simonie-Lafontaine J, Sagan C, Verrielle V, Antoine M et al. Pathological and Clinical Predictors for Response to Neoadjuvant Chemotherapy in Breast Cancer. Mod Pathol 2003; 16: 162 39A.